Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
6 USD | -5.36% | -5.36% | +26.85% |
Feb. 20 | Sigyn Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
2023 | Sigyn Therapeutics, Inc. Appoints Jerry Deciccio as Chief Financial Officer | CI |
Financials (USD)
Sales 2022 | - | Sales 2023 | - | Capitalization | 6.08M |
---|---|---|---|---|---|
Net income 2022 | -2M | Net income 2023 | -4M | EV / Sales 2022 | - |
Net Debt 2022 | 1.87M | Net Debt 2023 | 2.47M | EV / Sales 2023 | - |
P/E ratio 2022 |
-2.13
x | P/E ratio 2023 |
-1.25
x | Employees | 5 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 0% |
1 day | -5.36% | ||
1 week | -5.36% | ||
Current month | +9.09% | ||
6 months | -16.67% | ||
Current year | +26.85% |
Managers | Title | Age | Since |
---|---|---|---|
Craig Roberts
FOU | Founder | 71 | 19-10-18 |
James Joyce
CEO | Chief Executive Officer | 62 | 19-10-18 |
Jerry DeCiccio
DFI | Director of Finance/CFO | 67 | Dec. 11 |
Members of the board | Title | Age | Since |
---|---|---|---|
James Joyce
CEO | Chief Executive Officer | 62 | 19-10-18 |
James W. Dorst
BRD | Director/Board Member | 69 | 22-10-09 |
Richa Nand
BRD | Director/Board Member | 50 | 22-10-09 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-30 | 6 | -5.36% | 290 |
Delayed Quote OTC Markets, April 30, 2024 at 10:12 am EDT
More quotesChiffre d''affaires - Rate of surprise
- Stock Market
- Equities
- SIGY Stock